A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THREE PREPARATIONS OF LOW-DOSE ORAL ALPHA INTERFERON IN HIV-INFECTED PATIENTS WITH CD4+ COUNTS >= 50 AND <= 350 CELLS/MM3: